Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically- or cytologically- confirmed metastatic breast adenocarcinoma~* No HER2 overexpression or gene amplification~* No previous therapy for metastatic breast cancer is allowed~* Age 18-75 years~* At least 12 months interval since prior adjuvant therapy with taxanes and/or anthracyclines~* Measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions)~* Performance status (WHO) 0-2~* Adequate liver (serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the UNL in the presence of liver metastases)~* Adequate renal function (serum creatinine \<1.5 times the upper normal limit~* Adequate bone marrow function (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L)~* Written informed consent~Exclusion Criteria:~* Active infection~* Brain metastases~* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)~* History of stroke~* Anticoagulation therapy (except of low dose aspirin \<325mg)~* Other invasive malignancy except nonmelanoma skin cancer~* Psychiatric illness or social situation that would preclude study compliance~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bevacizumab-\>Epirubicin-\>Docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).